FLT3 and acute myeloid leukemia: AHR agonists can inhibit AML stem cells and induce leukemic stem cell differentiation by the induction of monocyte and/or granulocyte markers in patients with Flt3-ITD, and the agonists seem to have synergistic effects with the Flt3 inhibitor gilteritinib [215].